Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244829 · ClinicalTrials.gov registry record · Phase 1
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00244829 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center.
The verdict
NCT00244829, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate after a donor stem cell transplant may prevent the recurrence of Philadelphia chromosome-positive leukemia. PURPOSE: This phase I/II trial is studying the side effects of giving imatinib mesylate after a donor stem cell transplant and to see how well it works in treating patients with Philadelphia chromosome-positive leukemia.
Interventions
- DRUG imatinib mesylate
- PROCEDURE adjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244829
The ClinicalTrials.gov registry entry for NCT00244829 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which imatinib mesylate is the first listed.
NCT00244829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244829 about?
NCT00244829 is a clinical study titled "Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia". RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate after a donor stem cell transplant may prevent the recurrence of Philadelphia chromosome-positive leukemia. PURPOSE: This phase I/II trial is studying th...
What is the current status of trial NCT00244829?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-01. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00244829?
The interventions under investigation include: imatinib mesylate (DRUG), adjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00244829?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.